Understanding the risk of NMS in young patients

A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years.

DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market – Biotech Investments

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris continues to grow in the first quarter of 2024 and creates digital access to the

April 17, 2024

Pfizer and BioNTech’s Covid-19 vaccine receives recommendation

The updated vaccine is intended to treat children aged five years and above with Covid-19. Credit: Alexxndr/Shutterstock.com. Pfizer and BioNTech have received a marketing authorisation

August 31, 2023

Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug

Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: Gilead now owns 30% of Assembly Biosciences: The

December 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.